Stock Analiz

Mannatech Inc. MTEX

Medicinal Chemicals and Botanical Products · data as of November 13, 2026

$6.30Market cap $12M
Open the interactive analysis →

Mannatech Inc. (MTEX) is a healthcare company listed in the US with a market value of about $12M. In the twelve months to September 30, 2026 it had revenue of $103M and net income of -$425000, a net margin of -0.4%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is value (1/5); the weakest is future growth (0/5).

Key numbers: 5-year revenue growth of -7% a year, a 5-year average ROIC of 0%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% above the current price.

About Mannatech

Mannatech is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $190M in 2014 to $108M in 2025, a decline of about 5.0% a year. It was profitable in 4 of the last 10 years in our data. It spends 1% of revenue on research and development.

Score: 0.6 / 5

Value1/5
Future growth0/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • ROE above 15%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.1
P/B2.3
EV/EBITDA6.4
PEG—
Dividend yield0.00%
FCF yield-5.3%
Shareholder yield0.0%
Intrinsic value vs. price+96%

Growth and quality

Revenue growth (1 yr)-8.3%
Revenue growth (5 yrs, per year)-6.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2.2%
ROIC (5-yr avg.)0.1%
Profitable years (of last 10)4
Years paying a dividend8

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$103M$108M$118M$132M$137M$160M$151M$158M$174M$177M$180M
Net income-$425000-$15M$2M-$2M-$4M$10M$6M$3M-$4M-$2M-$586000
Free cash flow-$648000-$4M$2M-$3M-$4M$10M$5M$4M-$3M$9M-$2M
EPS (diluted)$-0.31$-8.00$1.32$-1.20$-2.35$4.71$2.77$1.35$-1.53$-0.66$-0.22
Net margin-0.4%-14.1%2.1%-1.7%-3.3%6.2%4.1%2.1%-2.2%-1.0%-0.3%
ROIC—-23.2%6.6%-5.1%-1.6%23.5%10.2%13.0%-0.3%4.9%1.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Mannatech stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 96% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Mannatech pay a dividend?

Not currently.

Is Mannatech a good stock to buy?

We do not give buy or sell advice. Mannatech scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.